//
Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Richard Roden

Ph.D.
(410) 502-5161 (p)
Interests

Pathology Oncology Gynecology and Obstetrics

Titles

Professor
Primary Appointment in Pathology; Secondary Appointments in Gynecology and Obstetrics, and Oncology
Member, Graduate Program in Pathobiology


 

Research Summary

The oncogenic genotypes of human papillomavirus (HPV), typified by HPV16, are the primary etiologic agent of cervical cancer. Papillomavirus has only two capsid proteins, L1 and L2. Both capsid proteins represent promising targets for prophylactic intervention. Our primary research goal is to prevent cervical cancer through the development of a preventative vaccine that is active against all oncogenic types of HPV.
Little is known about the pathogenesis of ovarian cancer and there is currently no screening test for its detection while still confined to the ovary. Our goal is to identify novel tumor antigens of significance in the biology of ovarian cancer and applicable as biomarkers for early detection or targets for immunotherapy. 

 

Journal Citations

Bazzaro, M.; Lee, M.K.; Zoso, A.; Stirling, W.L.; Santillan, A.; Shih Ie, M.; Roden, R.B. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res. 2006 Apr 1;66(7):3754-3763.
Roden, R.; Wu, T.C. How will HPV vaccines affect cervical cancer? Nat Rev Cancer. 2006 Oct;6(10):753-763.
Berg, M.; Gambhira, R.; Siracusa, M.; Hoiczyk, E.; Roden, R.; Ketner, G. HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice. Vaccine. 2007 Apr 30;25(17):3501-3510.
Lin, Y.Y.; Alphs, H.; Hung, C.F.; Roden, R.B.; Wu, T.C. Vaccines against human papillomavirus. Front Biosci. 2007;12:246-264.
Peng, S.; Trimble, C.; Wu, L.; Pardoll, D.; Roden, R.; Hung, C.F.; Wu, T.C. HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res. 2007 Apr 15;13(8):2479-2487.
Roden, R.B.; Monie, A.; Wu, T.C. Opportunities to improve the prevention and treatment of cervical cancer. Current molecular medicine. 2007 Aug;7(5):490-503.
Tesfaye, A.; Di Cello, F.; Hillion, J.; Ronnett, B.M.; Elbahloul, O.; Ashfaq, R.; Dhara, S.; Prochownik, E.; Tworkoski, K.; Reeves, R.; Roden, R.; Ellenson, L.H.; Huso, D.L.; Resar, L.M. The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res. 2007 May 1;67(9):3998-4004.
Alphs, H.H.; Gambhira, R.; Karanam, B.; Roberts, J.N.; Jagu, S.; Schiller, J.T.; Zeng, W.; Jackson, D.C.; Roden, R.B. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5850-5855.
Bazzaro, M.; Lin, Z.; Santillan, A.; Lee, M.K.; Wang, M.C.; Chan, K.C.; Bristow, R.E.; Mazitschek, R.; Bradner, J.; Roden, R.B. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res. 2008 Nov 15;14(22):7340-7347.
Day, P.M.; Gambhira, R.; Roden, R.B.; Lowy, D.R.; Schiller, J.T. Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol. 2008 May;82(9):4638-4646.
Huh, W.K.; Roden, R.B. The future of vaccines for cervical cancer. Gynecol Oncol. 2008 May;109(2 Suppl):S48-56.
Hung, C.F.; Wu, T.C.; Monie, A.; Roden, R. Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev. 2008 Apr;222:43-69.
Kim, D.; Gambhira, R.; Karanam, B.; Monie, A.; Hung, C.F.; Roden, R.; Wu, T.C. Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine. 2008 Jan 17;26(3):351-360.
Kurman, R.J.; Visvanathan, K.; Roden, R.; Wu, T.C.; Shih Ie, M. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol. 2008 Apr;198(4):351-356.
Roden, R.B.; Gravitt, P.; Wu, T.C. Towards global prevention of human papillomavirus-induced cancer. Eur J Immunol. 2008 Feb;38(2):323-326.
Conway, M.J.; Alam, S.; Ryndock, E.J.; Cruz, L.; Christensen, N.D.; Roden, R.B.; Meyers, C. Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J Virol. 2009 Oct;83(20):10515-10526.
Gambhira, R.; Jagu, S.; Karanam, B.; Day, P.M.; Roden, R. Role of L2 cysteines in papillomavirus infection and neutralization. Virol J. 2009;6:176.
Jagu, S.; Karanam, B.; Gambhira, R.; Chivukula, S.V.; Chaganti, R.J.; Lowy, D.R.; Schiller, J.T.; Roden, R.B. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst. 2009 Jun 3;101(11):782-792.
Karanam, B.; Gambhira, R.; Peng, S.; Jagu, S.; Kim, D.J.; Ketner, G.W.; Stern, P.L.; Adams, R.J.; Roden, R.B. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine. 2009 Feb 11;27(7):1040-1049.
Karanam, B.; Jagu, S.; Huh, W.K.; Roden, R.B. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol. 2009 May-Jun;87(4):287-299.
Li, J.; Sherman-Baust, C.A.; Tsai-Turton, M.; Bristow, R.E.; Roden, R.B.; Morin, P.J. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer. 2009;9:244.
Lin, Z.; Bazzaro, M.; Wang, M.C.; Chan, K.C.; Peng, S.; Roden, R.B. Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res. 2009 Jan 15;15(2):570-577.
Lin, Z.; Yemelyanova, A.V.; Gambhira, R.; Jagu, S.; Meyers, C.; Kirnbauer, R.; Ronnett, B.M.; Gravitt, P.E.; Roden, R.B. Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2. Am J Pathol. 2009 Jan;174(1):136-143.
Schellenbacher, C.; Roden, R.; Kirnbauer, R. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol. 2009 Oct;83(19):10085-10095.
Tsai-Turton, M.; Santillan, A.; Lu, D.; Bristow, R.E.; Chan, K.C.; Shih Ie, M.; Roden, R.B. p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol. 2009 Jul;114(1):12-17.
Campo, M.S.; Roden, R.B. Papillomavirus prophylactic vaccines: established successes, new approaches. J Virol. 2010 Feb;84(3):1214-1220.
Daayana, S.; Elkord, E.; Winters, U.; Pawlita, M.; Roden, R.; Stern, P.L.; Kitchener, H.C. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer. 2010 Mar 30;102(7):1129-1136.
Day, P.M.; Kines, R.C.; Thompson, C.D.; Jagu, S.; Roden, R.B.; Lowy, D.R.; Schiller, J.T. In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection. Cell Host Microbe. 2010 Sep 16;8(3):260-270.
Jagu, S.; Kwak, K.; Garcea, R.L.; Roden, R.B. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine. 2010 Jun 17;28(28):4478-4486.
Jones, S.; Wang, T.L.; Shih Ie, M.; Mao, T.L.; Nakayama, K.; Roden, R.; Glas, R.; Slamon, D.; Diaz, L.A., Jr.; Vogelstein, B.; Kinzler, K.W.; Velculescu, V.E.; Papadopoulos, N. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010 Oct 8;330(6001):228-231
Karanam, B.; Peng, S.; Li, T.; Buck, C.; Day, P.M.; Roden, R.B. Papillomavirus infection requires gamma secretase. J Virol. 2010 Oct;84(20):10661-10670.
Kwak, K.; Yemelyanova, A.; Roden, R.B. Prevention of cancer by prophylactic human papillomavirus vaccines. Curr Opin Immunol. 2010 Dec 23.
Ma, B.; Roden, R.; Wu, T.C. Current status of human papillomavirus vaccines. J Formos Med Assoc. 2010 Jul;109(7):481-483.
Peng, S.; Monie, A.; Kang, T.H.; Hung, C.F.; Roden, R.; Wu, T.C. Efficient delivery of DNA vaccines using human papillomavirus pseudovirions. Gene Ther. 2010 Dec;17(12):1453-1464.

 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer